Rev Med Interne 2016 Oct 13
[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].
Related Questions
This question is part of a collaboration with RheumMadness and is specifically in reference to: Long-term outcomes of anifrolumab in SLE.
New comment by at Uniformed Services University of the Health Sciences (USUHS) ( January 31, 2025)
I agree @Megan M. Lockwood: I'll never forget my first anifrolumab case. An elderly woman with SLE whose subacute cutaneous lupus failed literally everything. It was...
Several speakers at ACR 2021 commented on the important role of drug levels in the management of these patients and cautioned against adding medicatio...
New comment by at Uniformed Services University of the Health Sciences (USUHS) ( March 1, 2023)
I order mycophenolic levels to ensure of adherence in my MMF and Myfortic patients. We really do not know of therapeutic level goals in our lupus patients.
New answer by at Uniformed Services University of the Health Sciences (USUHS) (January 25, 2025)
Hydroxychloroquine has an initial whole-blood half-life of around 5 days, while its terminal half-life is around 40 days (Costedeau-Chalumeau et al., PMID 27745934). The forme...